Literature DB >> 8244415

Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody.

N Ramos-DeSimone1, U M Moll, J P Quigley, D L French.   

Abstract

Two members of the matrix metalloproteinase (MMP)1 family of enzymes are expressed at elevated levels in highly aggressive human tumor cells and have been implicated in the catalytic functions of extracellular proteolysis. The zymogen forms of these enzymes are designated proMMP-2 and proMMP-9, also known as 72kDa and 92kDa type IV collagenases/gelatinases, respectively. The MMP family of enzymes can be activated in vitro by a number of compounds including the organomercurial 4-aminophenylmercuric acetate (APMA). The natural or in vivo activators of MMP-2 and MMP-9 are at present unknown. A partially purified preparation of MMP-9 was used to immunize mice for the isolation of monoclonal antibodies (mAbs). Three IgG1 mAbs were identified by immunoreactivity with purified MMP-9 and are designated 6-6B, 7-11C, and 8-3H. These mAbs react specifically with MMP-9 by ELISA and Western blot. Additionally, these mAbs react with N-glycanase treated 92kDa protein. These mAbs were tested for their ability to inhibit enzyme activation in a radio-labeled gelatin assay. The 6-6B mAb inhibited the activation of MMP-9, but had no effect on MMP-2. These mAbs are highly specific to human MMP-9 and the 6-6B mAb will be extremely useful for examining the autolytic and catalytic activity of MMP-9 in normal and abnormal biological processes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244415     DOI: 10.1089/hyb.1993.12.349

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  19 in total

1.  Gelatinase-B (matrix metalloproteinase-9; MMP-9) secretion is involved in the migratory phase of human and murine muscle cell cultures.

Authors:  M P Lewis; H L Tippett; A C Sinanan; M J Morgan; N P Hunt
Journal:  J Muscle Res Cell Motil       Date:  2000-04       Impact factor: 2.698

2.  Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia.

Authors:  K H Lim; Y Zhou; M Janatpour; M McMaster; K Bass; S H Chun; S J Fisher
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

3.  Induction of matrix metalloproteinase 9 expression in breast carcinoma cells by a soluble factor from fibroblasts.

Authors:  B P Himelstein; R J Muschel
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

4.  Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.

Authors:  Anurag Purushothaman; Ligong Chen; Yang Yang; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

5.  Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway.

Authors:  Veronica C Ardi; Philippe E Van den Steen; Ghislain Opdenakker; Bernhard Schweighofer; Elena I Deryugina; James P Quigley
Journal:  J Biol Chem       Date:  2009-07-16       Impact factor: 5.157

6.  The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.

Authors:  Hilary A Kenny; Swayamjot Kaur; Lisa M Coussens; Ernst Lengyel
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

7.  In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity.

Authors:  Ozlem Bozdagi; Vanja Nagy; Kimberly T Kwei; George W Huntley
Journal:  J Neurophysiol       Date:  2007-05-09       Impact factor: 2.714

8.  Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis.

Authors:  Veronica C Ardi; Tatyana A Kupriyanova; Elena I Deryugina; James P Quigley
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

9.  92-kd type IV collagenase (matrix metalloproteinase-9) activity in human amniochorion increases with labor.

Authors:  F Vadillo-Ortega; G González-Avila; E E Furth; H Lei; R J Muschel; W G Stetler-Stevenson; J F Strauss
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

10.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.

Authors:  Z S Galis; G K Sukhova; M W Lark; P Libby
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.